Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 9/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 4/20 | 0.39 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026661 | 0.91 | F2RL3 (0.40) | PTGESPPARGPPARAPTPN11F2RL3 | |
| SCHEMBL4023313 | 0.85 | PTGES (0.40) | PTGESPPARGPPARAPTPN11PPARD | |
| SCHEMBL4021807 | 0.82 | PTGES (0.60) | PTGESPPARGPPARAEDNRAEDNRB | |
| Hydrochloric Acid SCHEMBL4021808 | 0.81 | PTGES (0.59) | PTGESPPARGPPARAEDNRAEDNRB | |
| SCHEMBL4189990 | 0.79 | NR4A2 (0.41) | PTGESPPARAPPARD | |
| SCHEMBL3007431 | 0.77 | PTGES (0.49) | PTGESPPARGPPARAEDNRAPPARD | |
| SCHEMBL4023999 | 0.77 | PPARD (0.38) | PPARAPPARD | |
| SCHEMBL4027503 | 0.76 | PTGES (0.71) | PTGESPPARGPPARAEDNRAEDNRB | |
| SCHEMBL334036 | 0.75 | PTGES (0.49) | PTGESPPARGPPARAPTPN11EDNRA | |
| SCHEMBL334220 | 0.75 | PTGES (0.48) | PTGESPPARGPPARAPTPN11EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765775-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080146616-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146616-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, PTGS1, PTGER1 | PTGES 4/4885PPARG 693/4885PPARA 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.